| 1 |
Young JM, Williams DR, Thompson AAR. Thin Air, Thick Vessels：Historical and current perspectives on hypoxic pulmonary hypertension[J]. Front Med (Lausanne), 2019, 6: 93.
|
| 2 |
Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)[J]. Eur Heart J, 2016, 37(1): 67-119.
|
| 3 |
Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia[J]. Eur Respir J, 2019, 53(1): pii: 1801914.
|
| 4 |
Shimoda LA, Yun X, Sikka G. Revisiting the role of hypoxia-inducible factors in pulmonary hypertension[J]. Curr Opin Physiol, 2019, 7: 33-40.
|
| 5 |
Xiong PY, Potus F, Chan W, et al. Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension[J]. Hypertension, 2018, 71(1): 34-55.
|
| 6 |
Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension[J]. Proc Natl Acad Sci USA, 1995, 92(12): 5510-5514.
|
| 7 |
Choudhry H, Harris AL. Advances in Hypoxia-Inducible Factor Biology[J]. Cell Metab, 2018, 27(2): 281-298.
|
| 8 |
Semenza GL.Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology[J]. Annu Rev Pathol, 2014, 9(47-71)．
|
| 9 |
Kojima H, Tokunou T, Takahara Y, et al. Hypoxia-inducible factor -1 alpha deletion in myeloid lineage attenuates hypoxia-induced pulmonary hypertension[J]. Physiol Rep, 2019, 7(7): e14025.
|
| 10 |
Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling[J]. Nat Rev Mol Cell Biol, 2016, 17(10): 611-625.
|
| 11 |
Alkholy UM, Mohamed SA, Elhady M, et al. Vascular endothelial growth factor and pulmonary hypertension in children with beta thalassemia major[J]. J Pediatr (Rio J), 2019, 95(5): 593-599.
|
| 12 |
Zimmer A, Teixeira RB, Bonetto JH, et al. Effects of aerobic exercise training on metabolism of nitric oxide and endothelin-1 in lung parenchyma of rats with pulmonary arterial hypertension[J]. Mol Cell Biochem, 2017, 429(1-2): 73-89.
|
| 13 |
Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway[J]. Wiley Interdiscip Rev Dev Biol, 2015, 4(3): 215-266.
|
| 14 |
Ojiaku CA, Yoo EJ, Panettieri RA, Jr. Transforming Growth Factor beta1 Function in Airway Remodeling and Hyperresponsiveness. The Missing Link？[J]. Am J Respir Cell Mol Biol, 2017, 56(4): 432-442.
|
| 15 |
Liu Y, Cao Y, Sun S, et al. Transforming growth factor-beta1 upregulation triggers pulmonary artery smooth muscle cell proliferation and apoptosis imbalance in rats with hypoxic pulmonary hypertension via the PTEN/AKT pathways[J]. Int J Biochem Cell Biol, 2016, 77(Pt A): 141-154.
|
| 16 |
Velayati A, Valerio MG, Shen M, et al. Update on pulmonary arterial hypertension pharmacotherapy[J]. Postgrad Med, 2016, 128(5): 460-473.
|
| 17 |
Jaitovich A, Jourd′heuil D. A Brief Overview of Nitric Oxide and Reactive Oxygen Species Signaling in Hypoxia-Induced Pulmonary Hypertension[J]. Adv Exp Med Biol, 2017, 967: 71-81.
|
| 18 |
Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2013, 188(6): 639-646.
|
| 19 |
Heinemann SH, Hoshi T, Westerhausen M, et al. Carbon monoxide-physiology, detection and controlled release[J]. Chem Commun (Camb), 2014, 50(28): 3644-3660.
|
| 20 |
Ryter SW, Ma KC, Choi AMK. Carbon monoxide in lung cell physiology and disease[J]. Am J Physiol Cell Physiol, 2018, 314(2): C211-C227.
|
| 21 |
Rose P, Moore PK, Zhu YZ. H2S biosynthesis and catabolism: new insights from molecular studies[J]. Cell Mol Life Sci, 2017, 74(8): 1391-1412.
|
| 22 |
Chunyu Z, Junbao D, Dingfang B, et al. The regulatory effect of hydrogen sulfide on hypoxic pulmonary hypertension in rats [J]. Biochem Biophys Res Commun, 2003, 302(4): 810-816.
|
| 23 |
Pugliese SC, Poth JM, Fini MA, et al. The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes[J]. Am J Physiol Lung Cell Mol Physiol, 2015, 308(3): L229-252.
|
| 24 |
夏世金，吴俊珍，胡明冬. 低氧致炎与低氧性肺动脉高压[J/CD]. 中华肺部疾病杂志(电子版), 2014, 7(5): 563-565.
|
| 25 |
Wang J, Zhu MC, Kalionis B, et al. Characteristics of circular RNA expression in lung tissues from mice with hypoxiainduced pulmonary hypertension[J]. Int J Mol Med, 2018, 42(3): 1353-1366.
|
| 26 |
Zhou S, Jiang H, Li M, et al. Circular RNA hsa_circ_0016070 Is Associated with Pulmonary Arterial Hypertension by Promoting PASMC Proliferation[J]. Mol Ther Nucleic Acids, 2019, 18: 275-284.
|
| 27 |
王 坚，胡明冬，唐晓丹，等. 慢病毒介导环状RNA mmu-circ-0001033过表达抑制低氧性小鼠肺动脉平滑肌细胞增殖的实验研究[J/CD]. 中华肺部疾病杂志(电子版), 2018, 11(1): 39-43.
|
| 28 |
Luo Y, Dong HY, Zhang B, et al. miR-29a-3p attenuates hypoxic pulmonary hypertension by inhibiting pulmonary adventitial fibroblast activation[J]. Hypertension, 2015, 65(2): 414-420.
|
| 29 |
Yuan Y, Shen C, Zhao SL, et al. MicroRNA-126 affects cell apoptosis，proliferation, cell cycle and modulates VEGF/TGF-beta levels in pulmonary artery endothelial cells[J]. Eur Rev Med Pharmacol Sci, 2019, 23(7): 3058-3069.
|
| 30 |
Quan Y, Wang Z, Gong L, et al. Exosome miR-371b-5p promotes proliferation of lung alveolar progenitor type II cells by using PTEN to orchestrate the PI3K/Akt signaling[J]. Stem Cell Res Ther, 2017, 8(1): 138.
|
| 31 |
He X, Song S, Ayon RJ, et al. Hypoxia selectively upregulates cation channels and increases cytosolic[Ca(2+)] in pulmonary, but not coronary, arterial smooth muscle cells[J]. Am J Physiol Cell Physiol, 2018, 314(4): C504-C517.
|
| 32 |
Lai N, Lu W, Wang J. Ca(2+) and ion channels in hypoxia-mediated pulmonary hypertension[J]. Int J Clin Exp Pathol, 2015, 8(2): 1081-1092.
|
| 33 |
Fukuda K, Date H, Doi S, et al. Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017)[J]. Circ J, 2019, 83(4): 842-945.
|
| 34 |
Al-Naamani K, Hijal T, Nguyen V, et al. Predictive values of the electrocardiogram in diagnosing pulmonary hypertension[J]. Int J Cardiol, 2008, 127(2): 214-218.
|
| 35 |
Rich JD, Thenappan T, Freed B, et al. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension[J]. Int J Cardiol, 2013, 167(3): 669-676.
|
| 36 |
Ferrara F, Zhou X, Gargani L, et al. Echocardiography in Pulmonary Arterial Hypertension[J]. Curr Cardiol Rep, 2019, 21(4): 22.
|
| 37 |
Freed BH, Collins JD, Francois CJ, et al. MR and CT Imaging for the Evaluation of Pulmonary Hypertension[J]. JACC Cardiovasc Imaging, 2016, 9(6): 715-732.
|
| 38 |
Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension[J]. Eur Respir J, 2019, 53(1): pii: 1801904
|
| 39 |
Callan P, Clark AL. Right heart catheterisation: indications and interpretation[J]. Heart, 2016, 102(2): 147-157.
|
| 40 |
Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension[J]. Chest, 2006, 129(5): 1313-1321.
|
| 41 |
Anwar A, Ruffenach G, Mahajan A, et al. Novel biomarkers for pulmonary arterial hypertension[J]. Respir Res, 2016, 17(1): 88.
|
| 42 |
Ismail K, Roberts K, Manning P, et al. OSA and pulmonary hypertension：time for a new look[J]. Chest, 2015, 147(3): 847-861.
|
| 43 |
Klinger JR. Group Ⅲ Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and Treatments[J]. Cardiol Clin, 2016, 34(3): 413-433.
|
| 44 |
Valerio G, Bracciale P, Grazia D′agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease[J]. Ther Adv Respir Dis, 2009, 3(1): 15-21.
|
| 45 |
Harari S, Elia D, Humbert M. Pulmonary Hypertension in Parenchymal Lung Diseases: Any Future for New Therapies? [J]. Chest, 2018, 153(1): 217-223.
|
| 46 |
Vitulo P, Stanziola A, Confalonieri M, et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial[J]. J Heart Lung Transplant, 2017, 36(2): 166-174.
|
| 47 |
Dernaika TA, Beavin M, Kinasewitz GT. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease[J]. Respiration, 2010, 79(5): 377-382.
|
| 48 |
King TE, Jr., Brown KK, Raghu G, et al. BUILD-3: a randomized，controlled trial of bosentan in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2011, 184(1): 92-99.
|
| 49 |
Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial[J]. Ann Intern Med, 2013, 158(9): 641-649.
|
| 50 |
Corte TJ, Keir GJ, Dimopoulos K, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia[J]. Am J Respir Crit Care Med, 2014, 190(2): 208-217.
|
| 51 |
Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis[J]. N Engl J Med, 2010, 363(7): 620-628.
|
| 52 |
Han MK, Bach DS, Hagan PG, et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction[J]. Chest, 2013, 143(6): 1699-1708.
|
| 53 |
Nathan SD, Behr J, Collard HR, et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study[J]. Lancet Respir Med, 2019, 7(9): 780-790.
|
| 54 |
Mirrakhimov AE, Strohl KP. High-altitude Pulmonary Hypertension：an Update on Disease Pathogenesis and Management [J]. Open Cardiovasc Med J, 2016, 10: 19-27.
|
| 55 |
Kojonazarov B, Isakova J, Imanov B, et al. Bosentan reduces pulmonary artery pressure in high altitude residents[J]. High Alt Med Biol, 2012, 13(3): 217-223.
|
| 56 |
Xu Y, Liu Y, Liu J, et al. Meta-analysis of clinical efficacy of sildenafil, a phosphodiesterase type-5 inhibitor on high altitude hypoxia and its complications[J]. High Alt Med Biol, 2014, 15(1): 46-51.
|
| 57 |
Luks AM, Swenson ER, Bartsch P. Acute high-altitude sickness[J]. Eur Respir Rev, 2017, 26(143): pii: 160096
|
| 58 |
Kojonazarov B, Myrzaakhmatova A, Sooronbaev T, et al. Effects of fasudil in patients with high-altitude pulmonary hypertension[J]. Eur Respir J, 2012, 39(2): 496-498.
|
| 59 |
Lopez-Meseguer M, Quezada CA, Ramon MA, et al. Lung and heart-lung transplantation in pulmonary arterial hypertension[J]. PLoS One, 2017, 12(11): e0187811.
|
| 60 |
Abud EM, Maylor J, Undem C, et al. Digoxin inhibits development of hypoxic pulmonary hypertension in mice[J]. 2012, 109(4): 1239-1244.
|
| 61 |
Dai Z, Zhu MM, Peng Y, et al. Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF-2alpha Inhibitor[J]. Am J Respir Crit Care Med, 2018, 198(11): 1423-1434.
|
| 62 |
Mohsenin V. The emerging role of microRNAs in hypoxia-induced pulmonary hypertension[J]. Sleep Breath, 2016, 20(3): 1059-1067.
|
| 63 |
Wang J, Zhu M, Pan J, et al. Circular RNAs: a rising star in respiratory diseases[J]. Respir Res, 2019, 20(1): 3.
|